FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221076646> ?p ?o ?g. }

• W4221076646 abstract "Due to developed chemotherapy regimes higher rates of complete remissions are reached by myeloablative therapies with autologous stem cell or bone marrow transplantation with Hodgkin and Non Hodgkin lymphomas, with an increasing incidence up to 20% t-AML/MDS (Micallef et al. 2000, Pedersen Bjergaard et al. 2000). In the context of this work the occurrence of the translocations and their respective fusion transcript t(8; 21) /AML1/ETO, inv (16) /CBFB-MYH11, t(15; 17) /PML RARα and t(9; 22) /BCR ABL were investigated in 42 leucapheresates (33 patients with NHL and 9 healthy donors) by conventional and real-time PCR. Neither the translocations t(8; 21), inv(16) or t(9; 22) were detected in this work, although for t(8; 21) and t(9; 22) an occurrence has already been described (Bäsecke et al. 2002b, Biernaux et al. 1995). The translocation t(15, 17) was detected in 6 of 42 samples (including 2 healthy donors) in real-time PCR and in 2 of these 6 samples in the nested RT-PCR, thereby demonstrating an exceptionally high incidence in comparison to other publications. A higher average age and thus an increased exposure to genotoxic substances in the environment were not available. Patients and donors were treated with G-CSF, thus, all, the patients by additional chemotherapy, were exposed to an elevated genotoxicity. Nevertheless, the detection of the fusion transcripts exceeded by far the incidence of t-AML. It is possible that in the translocations show a transient genetic instability after chemotherapy or stem cell mobilization, which is not indicative of leukemia or there was a detection in non-vital or apoptotic cells. The development of malignant diseases is a multi-stage process in which a specific genetic aberration must be present, but is insufficient as the only trigger for the clinical disease process. Overall, it is assumed that both, the conventional chemotherapy and the myeloablative therapy with stem cell or bone marrow transplantation may be involved in the development of t-AML/MDS. Due to the high incidence of t-AML in the risk group of patients receiving chemotherapy an early diagnosis using molecular genetic parameters is desirable. The predicting of a screening on t-AML-associated translocations in high-risk patients before autologous stem cell or bone marrow transplantation is limited due to the frequent evidence of the transcripts without development of t-AML, since such evidence is not indicative. Molecular genetic and chronological long-term studies of must follow in order to make a prediction about the risk of t-AML/MDS in the collective of transcript-positive patients." @default.
• W4221076646 created "2022-04-03" @default.
• W4221076646 creator A5032185214 @default.
• W4221076646 date "2022-02-20" @default.
• W4221076646 modified "2023-09-30" @default.
• W4221076646 title "Nachweis zytogenetischer Aberrationen nach Chemotherapie zur diagnostischen Früherkennung therapieassoziierter hämatologischer Neoplasien" @default.
• W4221076646 doi "https://doi.org/10.53846/goediss-988" @default.
• W4221076646 hasPublicationYear "2022" @default.
• W4221076646 type Work @default.
• W4221076646 citedByCount "0" @default.
• W4221076646 crossrefType "dissertation" @default.
• W4221076646 hasAuthorship W4221076646A5032185214 @default.
• W4221076646 hasBestOaLocation W42210766461 @default.
• W4221076646 hasConcept C104317684 @default.
• W4221076646 hasConcept C120665830 @default.
• W4221076646 hasConcept C121332964 @default.
• W4221076646 hasConcept C126322002 @default.
• W4221076646 hasConcept C138626823 @default.
• W4221076646 hasConcept C143998085 @default.
• W4221076646 hasConcept C151730666 @default.
• W4221076646 hasConcept C2776694085 @default.
• W4221076646 hasConcept C2779338263 @default.
• W4221076646 hasConcept C2779343474 @default.
• W4221076646 hasConcept C54355233 @default.
• W4221076646 hasConcept C61511704 @default.
• W4221076646 hasConcept C71924100 @default.
• W4221076646 hasConcept C86803240 @default.
• W4221076646 hasConcept C90924648 @default.
• W4221076646 hasConceptScore W4221076646C104317684 @default.
• W4221076646 hasConceptScore W4221076646C120665830 @default.
• W4221076646 hasConceptScore W4221076646C121332964 @default.
• W4221076646 hasConceptScore W4221076646C126322002 @default.
• W4221076646 hasConceptScore W4221076646C138626823 @default.
• W4221076646 hasConceptScore W4221076646C143998085 @default.
• W4221076646 hasConceptScore W4221076646C151730666 @default.
• W4221076646 hasConceptScore W4221076646C2776694085 @default.
• W4221076646 hasConceptScore W4221076646C2779338263 @default.
• W4221076646 hasConceptScore W4221076646C2779343474 @default.
• W4221076646 hasConceptScore W4221076646C54355233 @default.
• W4221076646 hasConceptScore W4221076646C61511704 @default.
• W4221076646 hasConceptScore W4221076646C71924100 @default.
• W4221076646 hasConceptScore W4221076646C86803240 @default.
• W4221076646 hasConceptScore W4221076646C90924648 @default.
• W4221076646 hasLocation W42210766461 @default.
• W4221076646 hasOpenAccess W4221076646 @default.
• W4221076646 hasPrimaryLocation W42210766461 @default.
• W4221076646 hasRelatedWork W1580426574 @default.
• W4221076646 hasRelatedWork W1984877488 @default.
• W4221076646 hasRelatedWork W2089620537 @default.
• W4221076646 hasRelatedWork W2275480158 @default.
• W4221076646 hasRelatedWork W2323950372 @default.
• W4221076646 hasRelatedWork W2371214482 @default.
• W4221076646 hasRelatedWork W2464045689 @default.
• W4221076646 hasRelatedWork W2612577867 @default.
• W4221076646 hasRelatedWork W2929987155 @default.
• W4221076646 hasRelatedWork W4238089809 @default.
• W4221076646 isParatext "false" @default.
• W4221076646 isRetracted "false" @default.
• W4221076646 workType "dissertation" @default.